trending Market Intelligence /marketintelligence/en/news-insights/trending/4scS7LNfYLFZQgkrPs71Hg2 content esgSubNav
In This List

Sumitomo Dainippon unit's lung disease treatment rejected by US FDA

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Sumitomo Dainippon unit's lung disease treatment rejected by US FDA

Sumitomo Dainippon Pharma Co. Ltd.'s indirect unit Sunovion Pharmaceuticals Inc. said the U.S. Food and Drug Administration issued a complete response letter for its new drug application for SUN-101/eFlow.

The drug is used to treat airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

Sunovion, which is not required to conduct any further clinical trials for approval of the drug, said it will work with the FDA to determine a path forward.